ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital
D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $30.00 price objective on the stock. Several other brokerages have also weighed in on IBRX. Piper Sandler upgraded ImmunityBio from a “neutral” rating to an “overweight” rating and […]
D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $30.00 price objective on the stock. Several other brokerages have also weighed in on IBRX. Piper Sandler upgraded ImmunityBio from a “neutral” rating to an “overweight” rating and […]
